Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon
Stock Information for Xeris Biopharma Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.